NCT06854003 - BRAZAN Trial in Frontline MCL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

November 1, 2029

Study Completion Date

November 1, 2039

Conditions

Mantle Cell LymphomaLymphoma

Interventions

DRUG

Bendamustine

An Alkylating agent, multi-dose vial, via intravenous (into the vein) infusion per institutional standard of care.

DRUG

Rituximab

An Anti-CD20 antibody, single-use vials, via intravenous infusion per institutional standard of care.

DRUG

Cytarabine

An Antineoplastic, single dose vial via intravenous infusion per institutional standard of care.

DRUG

Zanubrutinib

A BTK inhibitor, capsule taken orally per protocol.

DRUG

Sonrotoclax

A BCL 2 Protein Inhibitor, immediate release tablet, taken orally per protocol.

Trial Locations (2)

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston